USPTO serial 85246561
GLYCOTOPE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- ORTIGA PALMER, RAMONA
- Law office
- LAW OFFICE 117 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with GLYCOTOPE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
13125 Berlin, DE
13125 Berlin, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC2100 PENNSYLVANIA AVE NWWASHINGTON, DC 20037-3202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; unprocessed artificial resins; unprocessed plastics; fertilising preparations; fire extinguishing compositions; tempering substances and soldering chemicals; chemical substances for fermenting and preserving food stuffs; tanning agents for use in the manufacture of leather; adhesives used in industry; bacteria and cell preparations and elements, fragments, fractions and lysates thereof, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment, bacteria and cell preparations for use in expression of engineered or glycosylated proteins and peptides; preparations containing bacteria and cells, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment; biological preparations for laboratories, except for medical or veterinary purposes, namely, for use in bacterial and cell engineering, cultivation, harvesting, protein production; chemical preparations for analysis in laboratories, namely, preparations for protein, peptide, engineered proteins and peptides, glycoproteins, glycosylation, antibody or antigen analysis, preparations comprising antibody reagents used for the detection of antigens; chemical preparations for scientific purposes; chemical reagents except for medical or veterinary purposes and biological reagents in the nature of reagents for use in protein production, bacterial and cell engineering, cultivation and harvesting, probes for detecting and analyzing molecules in protein or nucleotide arrays, except for medical or veterinary purposes; diagnostic preparations, except for medical or veterinary purposes; enzymes, proteins and related preparations for industrial purposes, namely, engineered proteins, glycosylated proteins, antibodies, enzymes for use in glycosylation, enzyme substrates, proteins used in the manufacture of cosmetics, beverages, food products and food supplements; ferments for chemical purposes, namely, yeast, bacterium, mold, or enzyme, that causes fermentation; in-vitro diagnostic reagents, other than for medical purposes, namely, for use in biochemistry, clinical chemistry and microbiology; carbohydrates for use in the manufacture of food or nutraceuticals; cultures of microorganisms, other than for medical or veterinary use, and cells and elements, fragments, fractions and lysates thereof, other than for medical or veterinary purposes, namely, cultures of microorganisms or cells other than for medical and veterinary use, microorganism or cell cultures for use in protein production, food manufacturing, scientific research, waste water treatment, cultures of microorganisms or cells for use in expression of proteins and peptides; expression systems for proteins and peptides comprising cells, particularly human cells and microorganisms, suitable for expressing engineered or glycosylated proteins or peptides, or capable of providing optimized glycosylation activity; milk ferments for chemical purposes | ACTIVE | — |
| 005 | Pharmaceutical preparations and veterinary preparations for pets and livestock, namely, all for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; sanitary preparations for medical purposes; dietetic sugar for medical use; food for babies; medical plasters; materials for dressings, namely, wound dressings, burn dressings, and surgery dressings; materials for dental filling, namely, fillings for teeth, and impression materials for dental purposes; disinfectants for hygienic purposes, medical instruments, sanitary purposes; preparations for destroying vermin; fungicides, herbicides; adjuvants for medical purposes; medicines for human purposes and veterinary purposes for pets and livestock, namely, all for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological preparations for medical purposes; dietetic food adapted for medical purposes; enzymes, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine, and as nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; vaccines; nutritional supplements, namely, carbohydrates for medical purposes, namely, for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of microorganisms for medical or veterinary purposes; cultures of cells, particularly human cells for medical or veterinary purposes; medicinal drinks; microorganisms, cells and preparations containing elements, fragments, fractions and lysates of microorganisms or cells for medical and veterinary purposes, namely, for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological therapeutics, namely, therapeutics containing cells, microorganisms, proteins, glycoproteins, peptides, glycopeptides or modified or conjugated versions thereof, all for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; milk ferments for pharmaceutical purposes, namely, for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; nutritional additives and nutritional supplement additives all for medical purposes for use in foods and dietary supplements for human consumption; nutrients for medical purposes, namely, nutritional supplements; sugar and carbohydrates for medical purposes, namely, therapeutically and prophylactically active sugar and carbohydrates, dietetic sugar and carbohydrates, sugar and carbohydrate replacements | ACTIVE | — |
| 042 | Medical laboratories, namely, consumer-authorized clinical laboratory testing services that report results directly to the patient; scientific and technological services and research and designer services relating thereto, namely, in the field of biotechnology, protein production, glycosylation, optimization of protein, antibody and enzyme activity, bacteria and cell engineering, cultivation and harvesting; industrial analysis and research services in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, bacteria and cell engineering, cultivation and harvesting; design and development of computer hardware and software; biological research; services of a chemical or biological laboratory; technical surveying; conducting scientific surveys in the field of biotechnology, bacterial and cell engineering, protein production, glycosylation; scientific research and development, namely, in the field of bacteriology, cytology, antibody technology, chemistry, immunology, cosmetics of expression systems in the nature of production or glycosylation of proteins, peptides, antibodies and enzymes, particularly for proteins and peptides; quality control for others; research and development of new products; research and development of new technologies for others in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, bacteria and cell engineering, cultivation and harvesting; technical and scientific consultancy in relation to biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, bacteria and cell engineering, cultivation and harvesting; research and development in the field of glycomics, expression systems in the nature of production or glycosylation of proteins, peptides, antibodies and enzymes, development and improvement of cells, cell lines and microorganisms, antibody-engineering, optimized biological therapeutics, nutraceuticals, food and nutritional supplements; scientific research, quality control, technical consultancy and product development in the field of proteins, antibodies, microorganisms and cells; scientific research and development in the field of microorganisms and cells | ACTIVE | — |
| 044 | Medical services and veterinary services; hygienic and beauty care for human beings and animals; agriculture, horticulture and forestry services, namely, vermin extermination for agriculture, pest control services for agriculture, horticulture or forestry; pharmaceutical advice; performance of medical services featuring clinical examinations; nutrition counseling; health consultancy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glycotope GmbH
- Other trademarks owned by Glycotope GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GLYCOTOPE
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 21, 2015 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 21, 2015 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 31, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 23, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 22, 2015 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 22, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 30, 2014 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Dec 29, 2014 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Nov 26, 2014 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Nov 26, 2014 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Nov 19, 2014 | APET | ASSIGNED TO PETITION STAFF | — |
| Nov 10, 2014 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Jun 6, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 5, 2014 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 4, 2014 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 4, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 10, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 10, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 9, 2013 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 5, 2013 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 5, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 18, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 17, 2013 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 15, 2013 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 19, 2013 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 19, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 22, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 20, 2012 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 20, 2012 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 20, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 23, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 21, 2012 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 21, 2012 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 21, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 27, 2011 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 1, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 1, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 27, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 26, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 24, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 24, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 6, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 1, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| May 12, 2011 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| May 4, 2011 | ALIE | ASSIGNED TO LIE | — |
| Apr 27, 2011 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 24, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 22, 2011 | NWAP | NEW APPLICATION ENTERED | — |